Media coverage about Eagle Pharmaceuticals (NASDAQ:EGRX) has trended positive on Sunday, according to Alpha One Sentiment. The research firm, a subsidiary of Accern, identifies positive and negative news coverage by monitoring more than 20 million blog and news sources in real-time. Alpha One ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Eagle Pharmaceuticals earned a news sentiment score of 0.27 on Alpha One’s scale. Alpha One also assigned news stories about the specialty pharmaceutical company an impact score of 0 out of 100, indicating that recent news coverage is extremely unlikely to have an effect on the company’s share price in the immediate future.
These are some of the media headlines that may have effected Alpha One Sentiment’s scoring:
- Eagle Pharmaceuticals Inc (EGRX): From a Technical Perspective, How Do They Look? – The Times (tuckermantimes.com)
- Hologic, Inc. (HOLX) has a value of $44.35 per share While Eagle Pharmaceuticals, Inc. (EGRX) is stand at $72.65 – Stocks Gallery (stocksgallery.com)
- Eagle Pharmaceuticals Inc (EGRX) Moves -0.73% – JCTY News (jctynews.com)
- Eagle Pharmaceuticals, Inc.’s (EGRX) noted a price change of -2.24% and Revance Therapeutics, Inc.’s (RVNC) closes … – Stocks Gallery (stocksgallery.com)
- Eagle Pharmaceuticals, Inc. to Present at Investor Conferences in June – Business Wire (press release) (businesswire.com)
Eagle Pharmaceuticals (NASDAQ:EGRX) traded down 0.88% during mid-day trading on Friday, reaching $72.01. The company’s stock had a trading volume of 421,210 shares. Eagle Pharmaceuticals has a 12-month low of $34.20 and a 12-month high of $97.15. The firm has a market cap of $1.10 billion, a PE ratio of 11.32 and a beta of 1.54. The company has a 50-day moving average price of $84.24 and a 200-day moving average price of $78.23.
Eagle Pharmaceuticals (NASDAQ:EGRX) last released its quarterly earnings results on Monday, May 8th. The specialty pharmaceutical company reported $1.42 earnings per share for the quarter, missing the consensus estimate of $1.44 by $0.02. The firm had revenue of $76.80 million for the quarter, compared to the consensus estimate of $70.10 million. Eagle Pharmaceuticals had a net margin of 20.06% and a return on equity of 25.63%. Eagle Pharmaceuticals’s quarterly revenue was up 159.5% compared to the same quarter last year. During the same period in the previous year, the company earned ($0.06) earnings per share. On average, equities research analysts expect that Eagle Pharmaceuticals will post $3.66 earnings per share for the current year.
A number of research analysts have recently weighed in on EGRX shares. Mizuho restated an “underperform” rating and issued a $66.00 target price on shares of Eagle Pharmaceuticals in a report on Friday, March 17th. Royal Bank of Canada restated an “outperform” rating and issued a $86.00 target price on shares of Eagle Pharmaceuticals in a report on Thursday, March 2nd. Zacks Investment Research upgraded Eagle Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Tuesday, May 2nd. ValuEngine upgraded Eagle Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Tuesday, May 16th. Finally, Piper Jaffray Companies set a $118.00 price target on Eagle Pharmaceuticals and gave the stock an “overweight” rating in a report on Tuesday, May 9th. Two research analysts have rated the stock with a sell rating, one has given a hold rating, three have given a buy rating and one has given a strong buy rating to the company’s stock. The stock presently has an average rating of “Hold” and an average target price of $90.00.
TRADEMARK VIOLATION NOTICE: This story was originally posted by sleekmoney and is the property of of sleekmoney. If you are reading this story on another publication, it was copied illegally and republished in violation of U.S. and international copyright laws. The legal version of this story can be viewed at https://sleekmoney.com/eagle-pharmaceuticals-egrx-earning-favorable-press-coverage-analysis-shows/1879643.html.
In other news, insider David Pernock purchased 450 shares of the stock in a transaction dated Thursday, March 9th. The shares were purchased at an average cost of $77.84 per share, with a total value of $35,028.00. Following the acquisition, the insider now directly owns 450 shares of the company’s stock, valued at $35,028. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, major shareholder Proquest Investments Iv, L.P. sold 54,180 shares of the stock in a transaction on Tuesday, April 25th. The shares were sold at an average price of $88.38, for a total value of $4,788,428.40. The disclosure for this sale can be found here. Over the last three months, insiders have bought 6,966 shares of company stock worth $553,560 and have sold 412,918 shares worth $34,451,889. 18.80% of the stock is owned by corporate insiders.
Eagle Pharmaceuticals Company Profile
Eagle Pharmaceuticals, Inc is a specialty pharmaceutical company. The Company focuses on developing and commercializing injectable products in the critical care and oncology areas. The Company’s product portfolio includes products, including Argatroban; Ryanodex; docetaxel injection, non-alcohol formulation; and Bendeka.
This story was originally published by sleekmoney (https://sleekmoney.com) and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at https://sleekmoney.com/eagle-pharmaceuticals-egrx-earning-favorable-press-coverage-analysis-shows/1879643.html
Receive News & Ratings for Eagle Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eagle Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.